KRAS oncogenic mutations lead to the continued activation of downstream molecules, and the KRAS/mitogen-activated protein kinase (MAPK) signaling pathway is strongly associated with the development of PC, both of which enhance the malignant potential of this cancer [18, 19]. The gene discussed is KRAS; the disease is pachyonychia congenita.